TL;DR: Titrate retatrutide by measured response, not by feel. Start low — 0.5 to 1 mg/week — reassess every 4 weeks, and step up only when the response plateaus while the dose stays tolerated. The ladder runs 1 → 2 → 4 → 6 → 9 → 12 mg/week, with 12 mg as the ceiling. The objective is the effective tolerated dose — the lowest dose that still works, at the highest level still tolerated.

When Does a Response Appear?

Timing is highly individual across research models. Some register a measurable appetite-pathway response within the first administration; others show nothing for several weeks. Neither pattern is informative on its own — and neither should prompt a change to the schedule.

The signal that matters is whether body-composition endpoints are changing across a period of weeks. That trend is the readout. The subjective, short-term "feel" of any single dose is not — it is too noisy to titrate against, in either direction.

The Titration Logic

Whether to titrate a model upward is a question of measured response, not elapsed time. The flowchart below maps the decision at each 4-week checkpoint. The specific doses are matched to the protocol's schedule, but the objective never changes: the lowest effective dose that remains well tolerated.

Research Protocol

Retatrutide titration logic

Goal: the lowest effective, highest tolerated dose. Begin low — 0.5 to 1 mg/week — and reassess every 4 weeks, adjusting within +0.5 to +5 mg/week as tolerated.

Hold — response advancing Escalate — response plateaued De-escalate — poorly tolerated
1mg/weekStart

●Advancing → hold at 1 mg, reassess next cycle

▲Plateaued → escalate to 2 mg

▼Not tolerated → reduce to 0.5 mg (gentlest start)

2mg/week

●Advancing → hold at 2 mg

▲Plateaued → escalate to 4 mg

▼Not tolerated → drop to 1 mg

4mg/week

●Advancing → hold at 4 mg

▲Plateaued → escalate to 6 mg

▼Not tolerated → drop to 2 mg

6mg/week

●Advancing → hold at 6 mg

▲Plateaued → escalate to 9 mg

▼Not tolerated → drop to 4 mg

9mg/week

●Advancing → hold at 9 mg

▲Plateaued → escalate to 12 mg

▼Not tolerated → drop to 6 mg

12mg/weekMax

●Advancing → hold at 12 mg

▲Ceiling reached — do not escalate beyond 12 mg

▼Not tolerated → drop to 9 mg

⚠
Halt the protocol immediately if the model presents: Pancreatitis · severe allergic reaction · thyroid nodule or neck mass.

Modeled on the Phase 3 trial titration arms (2–12 mg/week), with a conservative 0.5–1 mg/week lead-in below the trial starting dose. Optimal values vary by model and protocol.

Reading the Ladder

Each 4-week checkpoint resolves to one of three actions:

  • Hold — the response is still advancing on the current dose. Stay there and reassess at the next cycle. There is no benefit to escalating a dose that is still producing change.
  • Escalate — the response has plateaued while the dose remains well tolerated. Step up one rung (1 → 2 → 4 → 6 → 9 → 12 mg/week) and reassess in another four weeks.
  • De-escalate — the dose is poorly tolerated. Step back down one rung. Tolerability always takes precedence over advancing the schedule.

The ladder is deliberately uneven — small early steps (0.5–1 → 2 mg) widen to +3 mg near the top (6 → 9, 9 → 12) — and 12 mg/week is the ceiling. At the ceiling the protocol holds; it does not escalate further. The low starting dose is the floor: if 1 mg/week is poorly tolerated, reduce to 0.5 mg rather than dropping below.

The target is not the highest dose a model can reach. It is the effective tolerated dose — the lowest dose that still produces the response, sustained at the highest level that remains tolerable.

Halt Signals

Independent of the titration logic, three findings warrant halting the protocol immediately and seeking evaluation: pancreatitis, a severe allergic reaction, or a thyroid nodule or neck mass. These are not titration decisions — they are stop conditions.

Related Reading

For Research Use Only

The schedule and decision logic above describe in-vitro and in-vivo laboratory research protocols modeled on published trial data. Helix North supplies retatrutide strictly for research applications.